¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Genes and immunity."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • protective immunity
    ¹æ¾î¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
  • racial immunity
    ÀÎÁ¾¸é¿ª
  • relative immunity
    »ó´ë¸é¿ª
  • residual immunity
    ÀÜ¿©¸é¿ª
  • specific immunity
    ƯÀ̸鿪
  • sterilizing immunity
    ºÒÀӸ鿪
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • native immunity
    (¢¡innate immunity) ¼±Ãµ¸é¿ª
  • natural immunity
    ÀÚ¿¬¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
  • protective immunity
    ¹æ¾î¸é¿ª
  • racial immunity
    ÀÎÁ¾¸é¿ª
  • relative immunity
    »ó´ë¸é¿ª
  • residual immunity
    ÀÜ¿©¸é¿ª
  • specific immunity
    ƯÀ̸鿪
  • sterilizing immunity
    ºÒÀӸ鿪
  • transplacental immunity
    ŹݰæÀ¯¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antitoxic immunity
    Ç×µ¶(¼Ò)¼º ¸é¿ª(ù÷Ô¸áÈàõØóæ¹).
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(~Øóæ¹)
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • gut immunity
    Àå°ü¸é¿ª
  • herd immunity
    ±ºÁý¸é¿ª, Áý´Ü¸é¿ª
  • herd immunity
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, cross
    ±³Â÷¸é¿ª
  • immunity, gut
    Àå°ü¸é¿ª
  • immunity, herd
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, humoral
    ü¾×¼º¸é¿ª
  • immunity, innate
    ¼±Ãµ¸é¿ª
  • immunity, local
    ±¹¼Ò¸é¿ª
  • immunity, maternal
    ¸ð¼º¸é¿ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • familial immunity
    °¡Á·¸é¿ª.
  • gut immunity
    Àå°ü¸é¿ª
  • herd immunity
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • herd immunity
    ±ºÁý¸é¿ª, Áý´Ü¸é¿ª
  • histogenous immunity
    Á¶Á÷¸é¿ª.
  • humoral immunity
    ü¾×¼º ¸é¿ª
  • humoral immunity
    ü¾×¼º¸é¿ª
  • immunity
    ¸é¿ª,(Øóæ¹)
  • immunity
    ¸é¿ª(¼º)
  • immunity deficiency =immunodeficiency
    ¸é¿ª°áÇÌ(¡­ÌÀù¹).
  • immunity pattern
    ¸é¿ª¾ç½Ä, ¸é¿ªÇü.
  • immunity ³ª immunitas
    ¸é¿ª(¼º)(Øóæ¹àõ).
  • immunity, acquired
    ȹµæ¸é¿ª, ÈÄõ¼º¸é¿ª
  • immunity, active
    ´Éµ¿¸é¿ª
  • immunity, adoptive
    ÀÔ¾ç¸é¿ª, ÀÌÀԸ鿪
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SBLA sarcoma, breast and brain tumors, leukemia, laryngeal and lung cancer, and adrenal cortical carcinom...
VACTERL vertebral abnormalities, anal atresia, cardiac abnormalities, tracheoesophageal fistula and/or esoph...
A&A aid and attendance; awake and aware
ABCDES abnormal alignment, bones-periarticular osteoporosis, cartilage-joint space loss, deformities, margi...
ACFAO American College of Foot and Ankle Orthopedics and Medicine
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
FEC 5-fluorouracil , epirubicin , and cyclophosphamide
FAC 5-fluorouracil, doxorubicin , and cyclophosphamide
PUVA 5-methoxypsoralen and UVA
P(i) phosphate and inorganic phosphate
A and
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hand foot and mouth disease
    ¼öÁ·±¸ º´, ¼Õ¹ßÀÔ º´, ¼Õ¹ß ¹× ±¸°­ Áúȯ, ¼Õ-¹ß-±¸°­ Áúȯ
    1. ÄÛ»çŰ ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ »ý±ä µå¹® Àå ¹ÙÀÌ·¯½º¼º °¨¿° Áúȯ. 2. °æÁõÀ̳ª ´ë´ÜÈ÷ °¨¿°·ÂÀÌ ÀÖ´Â ¼Ò¾ÆÀÇ ¹ÙÀÌ·¯½º º´À¸·Î¼­, ÀÔ, ¼öÁ·¿¡ ¼öÆ÷¼º º´º¯À» º¼ ¼ö ÀÖ´Â °ÍÀÌ ±× Ư¡ÀÌ´Ù. 3. ÄÛ»çŰ ¹ÙÀÌ·¯½º A16ÀÇ °¨¿°À¸·Î ¼Õ, ¹ß, ÇÏÁö, ÀÔ¼Ó¿¡ ÀÛÀº ¼öÆ÷°¡ »ý±â´Â Áúº´. ÁÖ·Î Á¥¸ÔÀÌ¿¡°Ô Àß ³ªÅ¸³ª´Â °¨¿°ÁõÀε¥, 6°³¿ù ¹Ì¸¸ÀÇ Á¥¸ÔÀÌ¿Í 4¼¼ ÀÌ»óÀÇ ¾î¸°ÀÌ¿¡°Ô´Â µå¹°°Ô °¨¿°µÈ´Ù. ³²ÀÚ ¾î¸°ÀÌ¿¡°Ô ¸¹°í ¼ºÀο¡°Ôµµ ³ªÅ¸³­´Ù. ¿©¸§Ã¶¿¡ ÁÖ·Î ¹ßº´Çϰí 4~6Àϰ£ÀÇ Àẹ±â¸¦ °ÅÄ£´Ù. Áõ¼¼´Â ´ëü·Î °¡º±´Ù. 1957³â ij³ª´Ù Åä·ÐÅä¿¡¼­ À¯ÇàÇßÀ» ¶§ ·Îºó½¼ µîÀÌ ÀÌ Áõ¼¼¿¡ ´ëÇØ ±â·ÏÇß°í, ´º¿åÁÖ ÄÛ»çŰ¿¡¼­ óÀ½À¸·Î ÀÌ ¹ÙÀÌ·¯½º¸¦ ºÐ¸®½ÃŲ µ¥¼­ ±× Áö¹æ¸íÀ» µû¼­ ¸í¸íÇÏ¿´´Ù. ±× ´ç½Ã º´¿øÃ¼´Â ÄÛ»çŰ A16 ¹ÙÀÌ·¯½º¿´À¸³ª, ÈÄ¿¡ ÄÛ»çŰ A5, A10°ú ¿£Å×·Î ¹ÙÀÌ·¯½º 71Çü¿¡ ÀÇÇØ¼­µµ °°Àº Áõ¼¼ÀÇ º´ÀÌ ³ªÅ¸³­´Ù´Â °ÍÀÌ ¹àÇôÁ³´Ù. ÁÖ·Î ºñ¸» °¨¿°, °æ±¸ °¨¿°À¸·Î Àü¿°µÈ´Ù.
  • Harris and Ray test
    Ç츮½º-·¹ÀÌ ½ÃÇè
    ¿äÁßÀÇ ºñŸ¹Î C¿¡ ´ëÇÑ ¹Ì·® ÀûÁ¤¹ý.
  • head and neck cancer
    µÎ°æºÎ ¾Ï
    ¸Ó¸®¿Í ¸ñ ºÎÀ§¿¡ »ý±â´Â ¾Ï.
  • heat and cold therapy
    ³Ã¿Â ¿ä¹ý
    Â÷°¡¿î ÆÐµå¿Í ¶ß°Å¿î ÆÐµå¸¦ ¹ø°¥¾Æ°¡¸ç º´¼Ò¿¡ ´ë°í Ç÷¾× ¼øÈ¯À» ÃËÁø½Ã۰í ÅëÁõÀ» ¿ÏÈ­½ÃŰ´Â ¹æ¹ý.
  • heating and cooling temperature-place-time profile
    °¡¿­ ¹× ³Ã°¢ ¿Âµµ-À§Ä¡-½Ã°£ Çü
  • Hines and Brown test
    ÇÏÀνº ºê¶ó¿î ½ÃÇè
    ¾óÀ½ ¹°¿¡ ÇÑÂÊ ¼ÕÀ» ´ã±×°í Ç÷¾ÐÀÇ ¹ÝÀÀÀ» ÃøÁ¤ÇÑ´Ù °úµµ·Î Ç÷¾ÐÀÌ »ó½ÂÇϸé ÀáÀ缺 °íÇ÷¾Ð »óŸ¦ ¶æÇÑ´Ù.
  • incision and drainage
    Àý°³ ¹è³ó
    »óó, ±Ë¾ç, °øµ¿¿¡¼­ ¾×ü³ª ¹è¼³¹°À» ü°èÀûÀ¸·Î ¹èÃâ½ÃŰ´Â °Í.
  • infant and child
    ¿µÀ¯¾Æ, À¯¼Ò¾Æ
    ¿µ¾Æ±â·ÎºÎÅÍ »çÃá±â±îÁöÀÇ »ç¶÷.
  • inlay with pin and post
    À¯Á¤ Àη¹ÀÌ
    Àη¹ÀÌü¿¡ Æ÷½ºÆ® ¶Ç´Â ÇÉÀ» º´¿ëÇÏ¿© º¸Áö·ÂÀ» °­È­½ÃŲ °Í.
  • lateral and protrusive excursion
    Ãø¹æ ¹× Àü¹æ Á¢ÃË ¿îµ¿
  • lateral cord and associated anterior cornual syndrome
    Ãø»è µ¿Ãø Àü°¢ ÁõÈıº
  • maternity and infant hygiene
    ¸ð¼º ¿µ¾Æ À§»ý, ¸ð¼º ¿µ¾Æ À§»ýÇÐ
  • maximum and minimum thermometer
    ÃÖ°í ÃÖÀú ¿Âµµ°è
  • metal backing with pin and post
    À¯Á¤ ¼³¸éÆÇ
    ÀüÄ¡ºÎ °¡°øÄ¡ÀÇ ¼³¸é ¹× ¼Õ½ÇÃø ÀÎÁ¢¸éÀÇ ÀϺθ¦ ÇǺ¹ÇÏ´Â ¼³¸éÆÇ¿¡
  • mixed small and large cell lymphoma
    È¥ÇÕ¼º ´ë¼Ò¼¼Æ÷ ¸²ÇÁÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
genes, bcl-2 The B-cell leukaemia/lymphoma-2 genes, responsible for blocking apoptosis in normal cells, and associated with follicular lymphoma when overexpressed. Overexpression results from the t(14;18) translocation. The human c-bcl-2 gene is located at 18q24 on the long arm of chromosome 18.
(12 Dec 1998)
genes, BRCA1 Tumour suppressor genes located on human chromosome 17q12-21. The mutation of these genes is associated with the formation of familial breast and ovarian cancer.
(12 Dec 1998)
genes, breast cancer susceptibility Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. Howeverm, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. See related entries to: BRCA1; BRCA2; Breast cancer, familial.
(12 Dec 1998)
genes, cdc Genes that code for proteins that regulate the cell division cycle. These genes form a regulatory network that culminates in the onset of mitosis by activating the p34cdc2 protein (protein p34cdc2).
(12 Dec 1998)
genes, dcc Tumour suppressor genes located in the 18q21-qter region of human chromosome 18. The absence of these genes is associated with the formation of colourectal cancer (dcc stands for deleted in colourectal cancer). The products of these genes show significant homology to neural cell adhesion molecules and other related cell surface glycoproteins.
(12 Dec 1998)
genes, dominant Genes that are reflected in the phenotype both in the homozygous and the heterozygous state.
(12 Dec 1998)
genes, env DNA sequences that form the coding region for the viral envelope (env) proteins in retroviruses. The env genes contain a cis-acting RNA target sequence for the rev protein (= gene products, rev), termed the rev-responsive element (rre).
(12 Dec 1998)
genes, erba Retrovirus-associated DNA sequences (erythroblastosis virus, avian, hence erba) originally isolated from the avian erythroblastosis virus. The c-erba proto-oncogene encodes the thyroid hormone receptors (receptors, thyroid hormone). Two distinct c-erba proto-oncogenes have been identified, erba-alpha and erba-beta, each giving rise to at least two proteins. Erba-alpha is located at 17q21 on the long arm of chromosome 17. Erba-beta is located at 3p24 on the short arm of chromosome 3. The v-erba oncogene potentiates cell transformation through inhibition of spontaneous differentiation of cells already transformed by the v-erbb gene and eliminates growth requirements of transformed erythroblasts.
(12 Dec 1998)
genes, erbb Retrovirus-associated DNA sequences (erbb) originally isolated from, or related to, the avian erythroblastosis virus (aev). These genes code for the epidermal growth factor receptor (egfr) family of receptors which is important in the control of normal cell proliferation and in the pathogenesis of human cancer. The genes include erbb-1 (genes, erbb-1), erbb-2 (genes, erbb-2), and erbb-3, all of which show abnormalities of expression in various human neoplasms.
(12 Dec 1998)
genes, erbb-1 Retrovirus-associated DNA sequences (erbb) originally isolated from the avian erythroblastosis virus (aev). The oncogene v-erbb arose by insertion of viral DNA into the c-erbb-1 proto-oncogene resulting in expression of a protein lacking the amino-terminal ligand-binding domain. V-erbb is the primary transforming gene of aev and abrogates the requirements for other mitogens. The proto-oncogene c-erbb-1 codes for the protein epidermal growth factor receptor (epidermal growth factor receptor-urogastrone). Overexpression of the gene occurs in a wide range of tumours, commonly squamous carcinomas of various sites and less commonly adenocarcinomas. The human c-erbb-1 gene is located at 7p12-13 on the short arm of chromosome 7.
(12 Dec 1998)
genes, erbb-2 Retrovirus-associated DNA sequences (erbb) related to the c-erbb-1 gene and identified by probes from c-erbb-1 or its avian viral homologue v-erbb. The proto-oncogene erbb-2 (c-erbb-2) codes for a protein that has structural features indicative of a growth factor receptor with close similarity to the epidermal growth factor (egf) receptor. Overexpression and amplification of the gene is associated with adenocarcinomas and with poor prognosis in breast carcinomas. The human c-erbb-2 gene is located at 17p12-21 on the short arm of chromosome 17.
(12 Dec 1998)
genes, fms Family of retrovirus-associated DNA sequences (fms) originally isolated from the susan mcdonough strain of feline sarcoma virus (sm-fesv). The proto-oncogene fms (c-fms) codes for a protein (csf-1) that is a member of the transmembrane tyrosine kinase growth factor receptor family. The human c-fms gene is located at 5q33.3 on the long arm of chromosome 5.
(12 Dec 1998)
genes, fos Retrovirus-associated DNA sequences (fos) originally isolated from the finkel-biskis-jinkins (fbj-msv) and finkel-biskis-reilly (fbr-msv) murine sarcoma viruses. The proto-oncogene protein c-fos codes for a nuclear protein which is involved in growth-related transcriptional control. The insertion of c-fos into fbj-msv or fbr-msv induces osteogenic sarcomas in mice. The human c-fos gene is located at 14q21-31 on the long arm of chromosome 14.
(12 Dec 1998)
genes, fungal The genetic material of fungi. It includes mating type genes of saccharomyces cerevisiae.
(12 Dec 1998)
genes, gag DNA sequences that form the coding region for proteins associated with the viral core in retroviruses. Gag is short for group-specific antigen.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Gog and Magog
    °î°ú ¸¶°î(»çÅÁ¿¡ ¹ÌȤµÇ¾î ÇÏ´Ã ³ª¶ó¿¡ ´ëÇ×ÇÏ´Â µÎ³ª¶ó)
  • H and C
    Çì·ÎÀÎ(heroin)°ú ÄÚÄ«ÀÎ(cocaine)À» ¼¯Àº °Í
  • Hereford and Worcester
    À×±Û·£µå ¼­ºÎÀÇ ÁÖ(1974³â ½Å¼³)
  • International Bank for Reconstruction and Development
    ±¹Á¦ ºÎÈï°³¹ßÀºÇà(IBRD)ÅëĪ(the world bank)
  • Jekyll and Hyde
    2ÁßÀΰÝÀÚÀÇ;2Áß ÀΰÝÀûÀÎ
  • Punch and Judy
    Àͻ콺·¯¿î ¿µ±¹ÀÇ ÀÎÇü±Ø
  • R&D,R.and D.
    research and development ¿¬±¸ °³¹ß
  • Royal and Ancient
    ·Î¿­ ¾Øµå ¿¡ÀÎ¼ÇÆ® °ñÇÁ Ŭ·´(¼¼°è ÃÖ°í,1754³â °³¼³)
  • Trinidad and Tobago
    ¼­Àεµ Á¦µµ¿¡ ÀÖ´Â ¿µ¿¬¹æ³»ÀÇ µ¶¸³±¹
  • and
    ±×¸®°í;¹×;¶ÇÇÑ;±×·¯ÀÚ;±×·¯¸é;(and/or=and or(newspapers and/or magazines ½Å¹® ¹× ¶Ç´Â ÀâÁö)
  • bait and switch
    À¯ÀÎ »ó¼úÀÇ
  • beall and endall
    ¿äÁ¡;Á¤¼ö;Áß¿äºÎ
  • buck and wing
    ÈæÀÎÀÇ ´í½º¿Í ¾ÆÀÏ·£µå°èÀÇ Å¬·Î±×´í½º°¡ ¼¯ÀÎ ·ÎÅ«·ÑÀÇ ºü¸¥ ÅÇ´í½º
  • cash-and-carry
    Çö±ÝÆÇ¸Å·Î Á¡µÎ¿¡¼­ ÀεµÇÏ´Â;Çö±Ý Á¡µÎ ÆÇ¸Å(Á¡);Çö±Ý Á¡µÎ ÆÇ¸ÅÁÖÀÇ
  • cat and mouse
    °í¾çÀÌ¿Í Áã(¾ÆÀÌµé ³îÀÌÀÇ Çϳª);°í¾çÀ̰¡ Á㸦 ³î¸®µí Çϱâ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á